

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/LO/0684	177109	Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension	Number Agreed	5	5	Date Agreed	13/10/2015	4	27/07/2016	4	Recruitment Finished
15/LO/0881	177217	A Phase III Multicenter, Double Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-149A One Daily Versus ATRIPLA Once-Daily in Treatment Naive HIV - 1 Infected Subjects	Number Agreed	5	5	Date Agreed	28/02/2018	5	08/08/2016	5	Recruitment Finished
15/LO/1324	181497	AMPLATZER Amulet Observational Post-Market Study	Number Agreed	10	10	Date Agreed	17/11/2019	19	24/08/2016	19	Recruitment Finished
15/LO/0564	173148	ARMOR3-SV: A Phase 3, Randomized, Open-Label, Multi-Center, Controlled Study of Galleterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) with Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)	Number Agreed	2	2	Date Agreed	01/02/2017	0	26/07/2016	0	Withdrawn By Sponsor
14/YH/0086	147377	RESPOND: Repositionable Lotus Valve System-Post Market Evaluation of Real World Clinical Outcomes	Range Agreed	15	30	Date Agreed	31/12/2015	121	01/10/2016	128	Recruitment Finished
15/LO/1600	182262	A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2-BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY	Number Agreed	6	6	Date Agreed	02/03/2018	1	04/10/2016	1	Withdrawn By Sponsor
16/NI/0034	194752	The Medtronic CoreValve™ Evolut R™ FORWARD Study	Number Agreed	5	5	Date Agreed	01/08/2017	11	01/11/2016	11	Recruitment Finished
16/EE/0098	201052	DIASOLVE: A randomised, crossover investigation to evaluate and compare the effectiveness, safety and feasibility of a novel dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for measuring fractional flow reserve (FFR) using intra-coron	Number Agreed	5	5	Date Agreed	30/11/2016	7	10/11/2016	7	Recruitment Finished
13/NW/0002	114402	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL? Haemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery	Range Agreed	10	32	Date Agreed	28/02/2014	5	22/11/2016	32	Recruitment Finished
13/NI/0138	120046	Portico I Study International long-term follow-up study of patients	Number Agreed	10	10	Date Agreed	30/06/2018	10	01/12/2016	10	Recruitment Finished
13/LO/0821	128690	A Phase 3 Open Label Safety Study of Elvitegravir/Cobicistat/Etricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV1 Positive Patients with Mild to Moderate Renal Impairment	Number Agreed	5	5	Not Available / Not Agreed			30/11/2016	1	Recruitment Finished
14/SC/0225	147356	A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV 1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF	Number Agreed	8	8	Not Available / Not Agreed			15/02/2017	6	Recruitment Finished
14/YH/1269	160993	Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of tapentadol intravenous solution for the treatment of post-surgical pain in children aged from birth to less than 2 years, including preterm neonate	Number Agreed	3	3	Date Agreed	31/08/2016	0	31/03/2017	0	Withdrawn By Sponsor
14/YH/1269	140294	A Phase 3, OpenLabel, Randomised, Parallel, 2Arm, MultiCenter Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Reg	Range Agreed	1	2	Not Available / Not Agreed		2	20/04/2017	2	Recruitment Finished
14/YH/0088	151005	Phase I study of KHK2823 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	Range Agreed	4	8	Date Agreed	01/02/2017	4	30/06/2017	4	Recruitment Finished
15/NW/0543	181870	A Multicentre, Randomised, Doubleblind, Placebo controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus	Number Agreed	2	3	Date Agreed	30/04/2017	0	30/06/2017	0	Recruitment Finished